迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02493 迈威生物-B

未开盘 10-12 16:08:15

20.400

+0.020

+0.10%

最高20.720	最低19.970	成交量9.56万
今开20.720	昨收20.380	日振幅3.68%
总市值91.19亿	流通市值9.61亿	总股本4.47亿
成交额192.92万	换手率0.20%	流通股本4,713万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"迈威生物-B","latestPrice":20.4,"timestamp":1791792495287,"preClose":20.38,"halted":0,"volume":95600,"delay":0,"changeRate":0.0009813542688910488,"floatShares":47130200,"shares":447000000,"eps":-2.43,"marketStatus":"未开盘","change":0.02,"latestTime":"10-12 16:08:15","open":20.72,"high":20.72,"low":19.97,"amount":1929196,"amplitude":0.036801,"askPrice":20.4,"askSize":1200,"bidPrice":20.04,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-2.422,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791855000000},"marketStatusCode":0,"adr":0,"listingDate":1777305600000,"exchange":"SEHK","adjPreClose":20.38,"openAndCloseTimeList":[[1791768600000,1791777600000],[1791781200000,1791792000000]],"volumeRatio":1.243496,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物-U","latestPrice":24.02,"timestamp":1791788400000,"preClose":24.78,"halted":0,"volume":5996600,"delay":0,"premium":"-27.55"}},"requestUrl":"/m/hq/s/02493","defaultTab":"news","newsList":[{"id":"2674889544","title":"迈威生物（688062）10月8日主力资金净买入221.75万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674889544","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674889544?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:26","pubTimestamp":1791505568,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月8日收盘，迈威生物报收于24.33元，下跌10.02%，换手率5.83%，成交量13.41万手，成交额3.35亿元。近5日资金流向一览见下表：迈威生物融资融券信息显示，融资方面，当日融资买入1932.52万元，融资偿还1397.44万元，融资净买入535.09万元。迈威生物主营业务：研发、生产以及销售创新型药物和生物类似药,以高效创新研发和产业化能力为支撑,通过治疗用生物制品的市场推广和销售获得商业利润。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900006082.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062","BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673451027","title":"破发股迈威生物跌10.02% 2022上市募34.8亿国泰海通保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2673451027","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673451027?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:48","pubTimestamp":1791449285,"startTime":"0","endTime":"0","summary":"中国经济网北京10月8日讯 迈威生物 今日收报24.33元，跌幅10.02%。该股目前处于破发状态。　　迈威生物于2022年1月18日在上交所科创板上市，发行股份数量为9990.00万股，发行价格为34.80元/股，保荐机构为海通证券股份有限公司，保荐代表人为王永杰、陈新军。　　迈威生物首次公开发行股票的发行费用合计1.85亿元，其中，保荐承销费1.55亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20261008/32390214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0276","02611","BK0188","IPOS","BK0201","BK1161","BK1564","601211","BK0183","BK0012","BK0184","02493","BK1147","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673022034","title":"10月8日迈威生物跌10.02%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2673022034","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673022034?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:36","pubTimestamp":1791448580,"startTime":"0","endTime":"0","summary":"证券之星消息，10月8日迈威生物跌10.02%，收盘报24.33元，换手率5.83%，成交量13.41万手，成交额3.35亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。中航优选领航混合发起A目前规模为0.62亿元，最新净值1.6486，较上一交易日上涨2.42%，近一年下跌21.6%。中航优选领航混合发起A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800021235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140836736","title":"迈威生物-B公布9月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1140836736","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140836736?lang=zh_cn&edition=full","pubTime":"2026-10-07 19:11","pubTimestamp":1791371514,"startTime":"0","endTime":"0","summary":"迈威生物-B于2026年10月7日发布的最新月报显示，截至2026年9月30日，公司注册股本共计人民币446,730,200元，包括人民币1元面值的H股47,130,200股和A股399,600,000股，二者与上月底持平，未发生增减变化。在已发行股份及库藏股方面，H股维持在47,130,200股，无库存股；A股已发行股数仍为398,407,631股，库存股为1,192,369股。月报显示，公司未披露本月任何股份期权计划或股权激励计划变动，亦无任何购回或注销股份的事项。本次公告由公司联席公司秘书王鹤飞女士签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671444362","title":"股市必读：迈威生物新发布《迈威生物第三届董事会第三次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2671444362","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671444362?lang=zh_cn&edition=full","pubTime":"2026-09-30 02:59","pubTimestamp":1790708347,"startTime":"0","endTime":"0","summary":"公司公告汇总迈威生物第三届董事会第三次会议决议公告迈威（上海）生物科技股份有限公司于2026年9月28日召开第三届董事会第三次会议，审议通过《关于对外投资暨联威创元引入投资人的议案》及《关于申请注册并使用香港交易所联讯通及授权相关事宜的议案》，表决结果均为全票通过；董事桂勋就前述对外投资事项回避表决。交易完成后，迈威生物预计持有联威创元71.21%股权，仍为其控股股东；本次交易不构成关联交易或重大资产重组。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000002791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2671291608","title":"迈威生物：公司认为既有FIC潜力品种、又有BIC或者FIH的品种，均有较大BD潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2671291608","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671291608?lang=zh_cn&edition=full","pubTime":"2026-09-29 15:34","pubTimestamp":1790667291,"startTime":"0","endTime":"0","summary":"证券之星消息，迈威生物(688062)09月29日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司有哪些管线目前具备BD的条件？迈威生物回复：尊敬的投资者，您好！ 公司长期坚持的研发策略是面向全球未被满足的临床需求做差异化创新，包括ADC、小核酸、TCE、抗炎单抗等等，公司认为既有FIC潜力品种、又有BIC或者FIH的品种，均有较大BD潜力，公司在BD方面资源和人员的投入也在逐年增加。但同时需要强调的是BD业务本身具有较大不确定性。感谢您的关注与支持！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900020540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671254840","title":"股市必读：迈威生物新发布《迈威生物对外投资暨联威创元引入投资人的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2671254840","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671254840?lang=zh_cn&edition=full","pubTime":"2026-09-29 01:17","pubTimestamp":1790615831,"startTime":"0","endTime":"0","summary":"公司公告汇总：迈威生物拟以82,500万元对全资子公司联威创元增资，并作价82,600万元转让TCE项目相关资产；联威创元将引入5名投资人合计出资16,000万元，交易后公司持股比例降至71.21%，仍为控股股东。公司公告汇总迈威生物对外投资暨联威创元引入投资人的公告迈威生物拟以货币资金82,500万元认购全资子公司联威创元新增注册资本8,250万元，并确认初始注册资本10万元对应出资额为100万元，增资完成后联威创元注册资本增至8,260万元，公司持股100%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900001594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670535702","title":"迈威生物(688062.SH)子公司联威创元拟引入投资人 旨在推动创新药业务发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2670535702","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670535702?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:02","pubTimestamp":1790604163,"startTime":"0","endTime":"0","summary":"上述增资均完成后，联威创元注册资本将由人民币8,260万元增加至人民币1.16亿元，公司预计仍持有联威创元71.21%股权，联威创元为公司合并报表范围内控股子公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","MEDX","688062","BK1574","IBBQ","LNGR","06978","BK0239","02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670258288","title":"迈威生物：第三届董事会第三次会议决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2670258288","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670258288?lang=zh_cn&edition=full","pubTime":"2026-09-28 21:29","pubTimestamp":1790602140,"startTime":"0","endTime":"0","summary":"证券日报网讯9月28日，迈威生物发布公告称，公司于2026年9月28日召开第三届董事会第三次会议，审议通过《关于对外投资暨联威创元引入投资人的议案》《关于申请注册并使用香港交易所联讯通及授权相关事宜的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885452883.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885452883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137590394","title":"迈威生物-B增资联威创元并引入1.6亿元Pre-A轮投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1137590394","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137590394?lang=zh_cn&edition=full","pubTime":"2026-09-28 21:11","pubTimestamp":1790601110,"startTime":"0","endTime":"0","summary":"迈威（上海）生物科技股份有限公司9月29日在上交所及联交所同步披露，对全资子公司联威创元（上海）生物技术有限公司进行增资并引入外部投资人。根据公告，迈威生物-B拟以人民币8.25亿元货币资金认购联威创元新增注册资本8,250万元，并确认联威创元初始注册资本10万元对应出资额100万元。在迈威生物-B增资后，联威创元计划与5名投资人签署Pre-A轮增资协议及股东协议，5名投资人将合计以1.6亿元现金认购联威创元新增注册资本1,600万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670234900","title":"迈威生物拟8.25亿元增资联威创元 同步对其转让8.26亿元TCE资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2670234900","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670234900?lang=zh_cn&edition=full","pubTime":"2026-09-28 19:32","pubTimestamp":1790595120,"startTime":"0","endTime":"0","summary":"9月28日，迈威生物（688062/02493）发布公告，公司拟向全资子公司联威创元现金增资8.25亿元，并将TCE项目相关专利、技术资料及注册商标以评估价8.26亿元转让给联威创元。同时，联威创元拟引入5名投资人，合计以1.6亿元认购新增注册资本，特定持股平台后续拟再认购1740万元。增资完成后，联威创元注册资本将增至1.16亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885344143.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885344143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669159966","title":"9月21日迈威生物涨5.41%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669159966","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669159966?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:40","pubTimestamp":1789980017,"startTime":"0","endTime":"0","summary":"证券之星消息，9月21日迈威生物涨5.41%，收盘报28.06元，换手率4.31%，成交量9.93万手，成交额2.78亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100020858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669159139","title":"迈威生物涨5.41%，中邮证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2669159139","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669159139?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:39","pubTimestamp":1789979998,"startTime":"0","endTime":"0","summary":"今日迈威生物（688062）涨5.41%，收盘报28.06元。2026年9月10日，中邮证券研究员盛丽华发布了对迈威生物的研报《商业化提速，Nectin-4 ADC迈入价值兑现关键期》，该研报对迈威生物给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为49.49%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中泰证券的祝嘉琦。迈威生物（688062）个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100020849.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668861188","title":"迈威生物：基于上半年的增长，对今年的药品销售收入预期较为乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=2668861188","media":"同花顺","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668861188?lang=zh_cn&edition=full","pubTime":"2026-09-20 13:22","pubTimestamp":1789881720,"startTime":"0","endTime":"0","summary":"近日，迈威生物-U(688062.SH)发布投资者关系活动记录表。其中提到，公司不对全年销售收入做具体数字的预期。但基于上半年的增长，对今年的药品销售收入预期较为乐观。迈威在成立之初就开始 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260920/c680089763.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260920/c680089763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668188865","title":"迈威生物：公司TCE平台的第一款分子LILRB4/CD3中美临床均已获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2668188865","media":"同花顺","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668188865?lang=zh_cn&edition=full","pubTime":"2026-09-20 13:19","pubTimestamp":1789881540,"startTime":"0","endTime":"0","summary":"近日，迈威生物-U(688062.SH)发布投资者关系活动记录表。其中提到，公司TCE技术平台采用创新的差异化设计策略，打造了自己的特色：1)自主开发的CD3抗体分子库。涵盖了从强效激活到温和激活 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260920/c680089733.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260920/c680089733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668900706","title":"迈威生物：2MW7141去年完成了海外授权，目前处于临床前阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2668900706","media":"同花顺","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668900706?lang=zh_cn&edition=full","pubTime":"2026-09-20 13:16","pubTimestamp":1789881360,"startTime":"0","endTime":"0","summary":"近日，迈威生物-U(688062.SH)发布投资者关系活动记录表。其中提到，公司自主研发的小核酸平台，拥有包括修饰、递送技术等多项专利。公司双靶点小核酸药物协同调控效应明确，临床前研究中展 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260920/c680089697.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260920/c680089697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668709900","title":"迈威生物：B7-H3 ADC的适应症主要面向鳞状非小细胞肺癌，下半年正式启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2668709900","media":"同花顺","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668709900?lang=zh_cn&edition=full","pubTime":"2026-09-20 13:08","pubTimestamp":1789880880,"startTime":"0","endTime":"0","summary":"近日，迈威生物-U(688062.SH)发布投资者关系活动记录表。其中提到，公司B7-H3ADC的适应症主要面向鳞状非小细胞肺癌。公司已完成关于肺鳞癌单药III期临床试验的沟通交流，下半年正式启动，有 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260920/c680089639.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260920/c680089639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668900363","title":"迈威生物：ST2单抗目前开展的是COPD的IIb期临床，期中分析有望在今年年内完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2668900363","media":"同花顺","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668900363?lang=zh_cn&edition=full","pubTime":"2026-09-20 12:03","pubTimestamp":1789876980,"startTime":"0","endTime":"0","summary":"近日，迈威生物-U(688062.SH)发布投资者关系活动记录表。其中提到，ST2单抗目前开展的是COPD的IIb期临床，期中分析有望在今年年内完成，并根据分析结果，沟通III期注册临床方案，届时会合规 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260920/c680089038.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260920/c680089038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668290086","title":"迈威生物：Nectin-4 ADC是公司目前有望最先获得商业化验证的原创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2668290086","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668290086?lang=zh_cn&edition=full","pubTime":"2026-09-20 11:54","pubTimestamp":1789876440,"startTime":"0","endTime":"0","summary":"近日，迈威生物-U(688062.SH)发布投资者关系活动记录表。其中提到，Nectin-4ADC是公司目前最为重要且有望最先获得商业化验证的原创新药。美国已经开展了针对拓扑异构酶ADC经治的TNBC的临床 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260920/c680088956.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260920/c680088956.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["IBBQ","02493","MEDX","LNGR","BK1574","BK1161","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114807153","title":"迈威生物-B(02493)三项议案高票获批 第四次临时股东会完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1114807153","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114807153?lang=zh_cn&edition=full","pubTime":"2026-09-17 22:32","pubTimestamp":1789655528,"startTime":"0","endTime":"0","summary":"2026年9月17日，迈威（上海）生物科技股份有限公司在上海召开2026年第四次临时股东大会。本次会议通过现场投票与网络投票相结合的方式进行。会议共有125名A股及H股股东及股东代表出席，合计代表表决权股份201,363,891股，占公司有表决权股份总数的45.1957%。其中，A股股东及代表124人，持股193,707,891股；H股股东及代表1人，持股7,656,000股。股东大会审议并分别以99.9099%、99.9099%及99.9051%的表决比例通过以下三项议案：。公告显示，本次股东大会无任何议案被否决。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mabwell.com","stockEarnings":[{"period":"1week","weight":-0.0192},{"period":"1month","weight":0.0049},{"period":"3month","weight":-0.1237},{"period":"6month","weight":-0.2619},{"period":"ytd","weight":-0.2619}],"compareEarnings":[{"period":"1week","weight":0.0096},{"period":"1month","weight":-0.0215},{"period":"3month","weight":-0.0029},{"period":"6month","weight":-0.0646},{"period":"1year","weight":-0.0768},{"period":"ytd","weight":-0.053}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"公司是一家全产业链布局的创新型生物制药公司,始终秉承“让创新从梦想变成现实”的愿景,践行“探索生命,惠及健康”的使命,通过源头创新,为患者提供疗效更好、可及性更强的生物创新药,满足全球未被满足的临床需求。公司主营业务为研发、生产以及销售创新型药物和生物类似药。公司主要产品为抗体、ADC药物和重组蛋白、小分子化学药等药物。公司荣誉:上海产业人才队伍建设工作“优秀案例奖”、澳洲会计师公会“认可雇主”、星耀榜“2021中国生物创新药最具成长性年度大奖”、中国医药人才品牌榜总榜及最具竞争力品牌等。","exchange":"SEHK","name":"迈威生物-B","nameEN":"MABWELL-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物-B(02493)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物-B,02493,迈威生物-B股票,迈威生物-B股票老虎,迈威生物-B股票老虎国际,迈威生物-B行情,迈威生物-B股票行情,迈威生物-B股价,迈威生物-B股市,迈威生物-B股票价格,迈威生物-B股票交易,迈威生物-B股票购买,迈威生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物-B(02493)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}